Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation
Open Access
- 1 June 2020
- journal article
- research article
- Published by Elsevier BV in Transplantation and Cellular Therapy
- Vol. 26 (6), 1077-1083
- https://doi.org/10.1016/j.bbmt.2019.11.028
Abstract
No abstract availableFunding Information
- Celgene
- Amgen
- Takeda Pharmaceuticals U.S.A.
- Novartis
- AstraZeneca
- Janssen Pharmaceuticals
This publication has 34 references indexed in Scilit:
- Undertreatment of Older Patients With Newly Diagnosed Multiple Myeloma in the Era of Novel TherapiesClinical Lymphoma Myeloma and Leukemia, 2018
- Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United StatesBlood Advances, 2017
- Autologous stem cell transplant for multiple myeloma patients 70 years or olderBone Marrow Transplantation, 2016
- Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent yearsBone Marrow Transplantation, 2014
- Older Patients with Myeloma Derive Similar Benefit from Autologous TransplantationTransplantation and Cellular Therapy, 2014
- Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patientsLeukemia, 2013
- New developments in conditioning regimens before auto-SCT in multiple myelomaBone Marrow Transplantation, 2011
- Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m2)Leukemia, 2003
- High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple MyelomaThe New England Journal of Medicine, 2003
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple MyelomaThe New England Journal of Medicine, 1996